Literature DB >> 20842594

Meningiomas.

Jeffrey Raizer1.   

Abstract

OPINION STATEMENT: Meningiomas are extra-axial dural-based tumors. They are the most common intracranial tumors, occur in mid to late life, and have a female predilection. Symptoms are a function of location. Meningiomas are usually benign, but atypical and malignant forms exist. Treatment is indicated for symptomatic lesions or when neurologic symptoms may shortly occur. Surgical resection can be curative; however, because of their location, some lesions are amenable only to partial resection. Radiation therapy is used for incompletely removed symptomatic lesions, lesions that are not surgically accessible, and small symptomatic lesions. For higher grade meningiomas, radiation is used after surgery. For lesions that recur or grow despite surgery and radiation, systemic chemotherapy can be tried. There is no optimal agent, but hydroxyurea is used most often with very modest success; hormonal approaches have not been successful. Targeting somatostatin receptors or receptor tyrosine kinases using novel agents appears to have some activity and is an area of clinical research.

Entities:  

Year:  2010        PMID: 20842594     DOI: 10.1007/s11940-010-0081-x

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  25 in total

Review 1.  Natural history of conservatively treated meningiomas.

Authors:  Z Herscovici; Z Rappaport; J Sulkes; L Danaila; G Rubin
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

2.  Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.

Authors:  S M Grunberg; M H Weiss; I M Spitz; J Ahmadi; A Sadun; C A Russell; L Lucci; L L Stevenson
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

Review 3.  Targeted drug therapy for meningiomas.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

4.  Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.

Authors:  S M Grunberg; M H Weiss
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

5.  Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience.

Authors:  Shigetoshi Yano; Jun-ichi Kuratsu
Journal:  J Neurosurg       Date:  2006-10       Impact factor: 5.115

6.  Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.

Authors:  H B Newton; S R Scott; C Volpi
Journal:  Br J Neurosurg       Date:  2004-10       Impact factor: 1.596

7.  The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.

Authors:  S E Kaba; F DeMonte; J M Bruner; A P Kyritsis; K A Jaeckle; V Levin; W K Yung
Journal:  Neurosurgery       Date:  1997-02       Impact factor: 4.654

8.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 9.  Meningeal tumors of childhood and infancy. An update and literature review.

Authors:  Arie Perry; Louis P Dehner
Journal:  Brain Pathol       Date:  2003-07       Impact factor: 6.508

10.  A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.

Authors:  J W Goodwin; J Crowley; H J Eyre; B Stafford; K A Jaeckle; J J Townsend
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.